NeuroPace To Report Second Quarter 2021 Financial Results on August 12, 2021
NeuroPace, Inc. (Nasdaq: NPCE) will report its financial results for Q2 2021 on August 12, 2021, after market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
NeuroPace, Inc. (Nasdaq: NPCE) will report its financial results for Q2 2021 on August 12, 2021, after market close. A conference call with management will follow at 1:30 p.m. PT/4:30 p.m. ET, accessible by dialing (844) 955-2173 for domestic or (914) 987-7949 for international participants. NeuroPace specializes in innovative medical devices for epilepsy, with its RNS System being the only brain-responsive neuromodulation platform available, providing personalized treatment to patients with drug-resistant epilepsy.
Positive
- The RNS System offers a unique solution for drug-resistant epilepsy, potentially improving patient outcomes.
- The upcoming Q2 2021 earnings report may provide insights into financial performance and future guidance.
Negative
- None.
Details
News Market Reaction – NPCE
The recorded move for NPCE in the trading session of this news was -1.22%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MOUNTAIN VIEW, Calif., July 22, 2021 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today announced it will report financial results for the second quarter of 2021 after market close on Thursday, August 12, 2021. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time /4:30 p.m. Eastern Time.
Investors interested in listening to the conference call may do so by dialing (844) 955-2173 for domestic callers or (914) 987-7949 for international callers, using conference ID: 2975459. Live audio of the webcast will be available on the “Investors” section of the company’s website at: https://investors.neuropace.com. The webcast will be archived and available for replay for at least 90 days after the event.
About NeuroPace, Inc.
Based in Mountain View, Calif., NeuroPace is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive neuromodulation platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients suffering from drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.
Investor Contact:
Gilmartin Group
Matt Bacso, CFA
investors@neuropace.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.